Bank of New York Mellon
RUBY

Bank of New York Mellon’s Rubius Therapeutics, Inc RUBY Stock Holding History

Bank of New York Mellon’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,990
Closed -$3.67K – 4472
2022
Q4 		$3.67K Hold
20,990
– – ﹤0.01% 4456
2022
Q3 		$9K Hold
20,990
– – ﹤0.01% 4516
2022
Q2 		$18K Sell
20,990
-126,267
-86% -$212K ﹤0.01% 4506
2022
Q1 		$811K Sell
147,257
-1,003
-0.7% -$6.37K ﹤0.01% 3438
2021
Q4 		$1.44M Sell
148,260
-42,349
-22% -$587K ﹤0.01% 3177
2021
Q3 		$3.41M Sell
190,609
-20,992
-10% -$457K ﹤0.01% 2693
2021
Q2 		$5.17M Buy
211,601
+18,708
+10% +$468K ﹤0.01% 2470
2021
Q1 		$5.11M Buy
192,893
+35,083
+22% +$512K ﹤0.01% 2439
2020
Q4 		$1.2M Buy
157,810
+6,934
+5% +$41.2K ﹤0.01% 3158
2020
Q3 		$755K Sell
150,876
-348
-0.2% -$1.84K ﹤0.01% 3283
2020
Q2 		$904K Buy
151,224
+20,053
+15% +$118K ﹤0.01% 3164
2020
Q1 		$583K Sell
131,171
-8,614
-6% -$64K ﹤0.01% 3280
2019
Q4 		$1.33M Buy
139,785
+14,530
+12% +$141K ﹤0.01% 3086
2019
Q3 		$984K Buy
125,255
+3,759
+3% +$43.8K ﹤0.01% 3190
2019
Q2 		$1.91M Buy
121,496
+33,092
+37% +$534K ﹤0.01% 2816
2019
Q1 		$1.6M Buy
88,404
+50,579
+134% +$776K ﹤0.01% 2902
2018
Q4 		$609K Buy
37,825
+8,357
+28% +$152K ﹤0.01% 3381
2018
Q3 		$707K Buy
+29,468
New +$674K ﹤0.01% 3463

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Bank of New York Mellon's RUBY Position: Q1 2023 in Review

Bank of New York Mellon sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 20,990 shares — an estimated $3.67K sold.

Bank of New York Mellon first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $5.17M in Q2 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Bank of New York Mellon reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 20,990 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $3.67K.
  • Bank of New York Mellon first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • Bank of New York Mellon's Rubius Therapeutics, Inc position peaked at $5.17M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Bank of New York Mellon's 13F filing for Q1 2023, filed 9 May 2023.